US FDA approves Strides' anti-anxiety drug
26 August 2014 | News | By BioSpectrum Bureau
US FDA approves Strides' anti-anxiety drug
market for generic Buspirone tablets was nearly $65 million
Strides Arcolab has announced that it has received approval from the United States Food and Drug Administration (US FDA) for its generic drug, Buspirone Hydrochloride tablets. The tablets are used for the treatment of anxiety disorders and the short-term relief from the symptoms of anxiety.
The approval has been granted for tablets in strengths 5 mg, 10 mg, 15 mg and 30 mg, the company informed. According to IMS data, the US market for generic Buspirone tablets was nearly $65 million in 2013.
"The product will be manufactured at the company's oral dosage facility at Bangalore and marketed directly by Strides in the US Market," the company said in a statement.
